The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Allergic basis of asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=74 Year: 2003
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Omalizumab inhibits allergen challenge-induced nasal response Source: Eur Respir J 2004; 23: 414-419 Year: 2004
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Targeting atopic inflammation: anti-IgE treatment Source: Annual Congress 2007 - Novel therapies for severe asthma Year: 2007
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003